Pelemans H[Author] - Search Results

Year	Number of Results
1994	1
1995	1
1996	4
1997	3
1998	4
2000	2
2001	3
2024	0

1

Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109.

Balzarini J, Wedgwood O, Kruining J, Pelemans H, Heijtink R, De Clercq E, McGuigan C. Balzarini J, et al. Among authors: pelemans h. Biochem Biophys Res Commun. 1996 Aug 14;225(2):363-9. doi: 10.1006/bbrc.1996.1181. Biochem Biophys Res Commun. 1996. PMID: 8753770 Free article.

2

Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1.

Pelemans H, Esnouf R, Dunkler A, Parniak MA, Vandamme AM, Karlsson A, De Clercq E, Kleim JP, Balzarini J. Pelemans H, et al. J Virol. 1997 Nov;71(11):8195-203. doi: 10.1128/JVI.71.11.8195-8203.1997. J Virol. 1997. PMID: 9343170 Free PMC article.

3

Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors.

Balzarini J, Pelemans H, Karlsson A, De ClercQ E, Kleim JP. Balzarini J, et al. Among authors: pelemans h. Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13152-7. doi: 10.1073/pnas.93.23.13152. Proc Natl Acad Sci U S A. 1996. PMID: 8917560 Free PMC article.

4

Characterization of the Rhizobium leguminosarum biovar phaseoli nifA gene, a positive regulator of nif gene expression.

Michiels J, D'hooghe I, Verreth C, Pelemans H, Vanderleyden J. Michiels J, et al. Among authors: pelemans h. Arch Microbiol. 1994;161(5):404-8. doi: 10.1007/BF00288950. Arch Microbiol. 1994. PMID: 8042903

5

Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase.

Rodríguez-Barrios F, Pérez C, Lobatón E, Velázquez S, Chamorro C, San-Félix A, Pérez-Pérez MJ, Camarasa MJ, Pelemans H, Balzarini J, Gago F. Rodríguez-Barrios F, et al. Among authors: pelemans h. J Med Chem. 2001 Jun 7;44(12):1853-65. doi: 10.1021/jm001095i. J Med Chem. 2001. PMID: 11384232

6

Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine.

Balzarini J, Pelemans H, Riess G, Roesner M, Winkler I, De Clercq E, Kleim JP. Balzarini J, et al. Among authors: pelemans h. J Infect Dis. 1997 Nov;176(5):1392-7. doi: 10.1086/517329. J Infect Dis. 1997. PMID: 9359746

7

A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781.

Balzarini J, Pelemans H, Esnouf R, De Clercq E. Balzarini J, et al. Among authors: pelemans h. AIDS Res Hum Retroviruses. 1998 Feb 10;14(3):255-60. doi: 10.1089/aid.1998.14.255. AIDS Res Hum Retroviruses. 1998. PMID: 9491916

8

Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).

Balzarini J, Pelemans H, Riess G, Roesner M, Winkler I, De Clercq E, Kleim JP. Balzarini J, et al. Among authors: pelemans h. Biochem Pharmacol. 1998 Mar 1;55(5):617-25. doi: 10.1016/s0006-2952(97)00506-6. Biochem Pharmacol. 1998. PMID: 9515572

9

Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors.

Pelemans H, Esnouf R, De Clercq E, Balzarini J. Pelemans H, et al. Mol Pharmacol. 2000 May;57(5):954-60. Mol Pharmacol. 2000. PMID: 10779379

10

A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152.

Pelemans H, Esnouf RM, Parniak MA, Vandamme AM, De Clercq E, Balzarini J. Pelemans H, et al. J Gen Virol. 1998 Jun;79 ( Pt 6):1347-52. doi: 10.1099/0022-1317-79-6-1347. J Gen Virol. 1998. PMID: 9634074

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

18 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year